Replies to post #5711 on Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

JPMorgan has initiated coverage on Enanta Pharmaceuticals (NASDAQ:ENTA) with an Overweight rating and a $17.00 price target,
...
JPMorgan estimates potential peak worldwide sales of over $1.5 billion for zelicapavir, with more than $1 billion in the U.S. alone, assigning a 70% probability of success

These two sentences are not compatible. 70% chance of a >1B annualized assets with good IP doesn't add up to 17 dollars a share. I don't have access to the report must have been some real mental gymnastics to get there
whatever